A Clinical Trial of Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell (AHSC) Transplantation for Acute Myeloid Leukemia (AML)

Inclusion Criteria (Initial Eligibility Screen): * Diagnosis of AML, not M3 * At least 10% of circulating leukocytes are AML blast cells * Age 18 through 75 * Sex male or female * Patient is considered a potential candidate for AHSCT Exclusion criteria (Initial Eligibility Screen): * Participation in another immunotherapy trial within 30 days * Presence of active malignancy other than AML * History of autoimmune disease requiring systemic treatment * ECOG performance status of 3 or 4 * Major organ system dysfunction * Recent (30 days) or current use of steroids other than topical skin preparations * History of allogeneic transplant * Patients who, for any reason are not deemed candidates for AHSCT Eligibility for autologous CTL Infusion: Inclusion Criteria: * Patient has CTL that are in sufficient number and are suitable for infusion * Patient is stable, afebrile, engrafted, ECOG status 0-2, in CR and received AHSCT 45 - 60 days earlier. Exclusion or delay criteria: * Temperature \> 38 C and/or known to be infected * Absence of engraftment ANC \> 500 and Plt \> 20,000 unsupported * Life expectancy less than 6 weeks * Autoimmune disease requiring systemic treatment. * ECOG performance status of 3 or 4 * Major organ system dysfunction